Plain-English translation of NCT06904313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are testing a new way to scan for prostate cancer using 18F-DCFPyL, a radioactive tracer that attaches to cancer cells. Instead of using the standard radiation dose, this study uses an extremely small amount—less than 1/20th of the usual dose—combined with advanced imaging technology to see if clear pictures are still possible. The goal is to create a safer scanning method that could be used more often for screening and monitoring prostate cancer.
Current prostate cancer scans work well but use significant radiation, which limits how often doctors can use them for screening and monitoring. This trial aims to prove that a much safer, low-radiation version of this scan can still detect cancer effectively, potentially allowing patients to be monitored more frequently without unnecessary radiation exposure.
You likely qualify if…
You likely don't qualify if…
You would visit the Nuclear Imaging Institute for a single imaging appointment. You would receive an injection of a very small amount of radioactive tracer, then lie in a PET scanner for up to 3 hours while images are taken. The entire process is non-invasive and painless—the only radiation exposure comes from the tiny amount of tracer, which is much lower than standard scans. Most of your time during the visit would involve waiting and scanning while researchers monitor image quality.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States